Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax plus azacitidine vs intensive chemotherapy in primary refractory AML (JALSG-AML224-PIF)
jRCTs041250076Phase 3Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Oct 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of venetoclax and azacitidine in acute myeloid leukemia (AML) (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Primary: CRc + MLFS rate after one course of study treatment. Started Oct 2025; status: recruiting.
02
Drugs
venetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCTs041250076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041250076.